The global automated breast ultrasound systems (ABUS) market is anticipated to register sizeable growth by 2030. The rising prevalence of breast cancer has dramatically fueled the need for advanced medical screening and diagnostic tools. Automated breast ultrasound systems (ABUS) can effectively address the limitations of existing breast cancer screening systems such as mammograms. It caters to challenges faced in identifying the presence of very small tumors that are often left undetected, especially in dense breast tissues.

Notable advancements in software technology will support the development of diagnostic imaging solutions for early cancer detection. For instance, in July 2021, cloud company Infor launched a new interoperability solution called FHIR Server catering to the healthcare sector by enhancing the efficiency of data analysis.

Various countries such as the U.S. are introducing favorable reimbursement policies for digital breast tomosynthesis and breast ultrasound. Such initiatives will empower women to undergo routine screening tests for breast cancer. Government support in managing healthcare expenses including public health insurance will drive patient interest in high-tech diagnostic technologies. Large organizations such as the American Cancer Society Cancer Action Network (ACSCAN) emphasize on the need for comprehensive coverage, enabling breast cancer screening for low-income groups.

The automated breast ultrasound systems (ABUS) industry is segregated into product, end-use, and region.

Based on the product, the market is bifurcated into automated breast ultrasound system (ABUS) and automated breast volume scanner (ABVS). Among these, ABUS product segment was valued at more than USD 950 million in 2021. Various concerns associated with existing breast cancer screening techniques such as discomfort or exposure to radiation are factors that will boost the popularity of ABUS.

Unlike mammograms, ABUS does not use compression, thus minimizing discomfort. The technology is safe for women of all age groups including younger females, pregnant women, and even lactating women. It can also be used to examine women with breast implants or post-operative scarring.

With respect to end-use, the industry is fragmented into specialty centers, hospitals, and diagnostic imaging centers. The ABUS market share from specialty centers is projected to exhibit over 14% CAGR from 2022-2030. Patients have a high preference for specialty hospitals as they provide access to substantial resources, extraordinary expertise, and favorable therapy programs. Studies have found that specialty centers have higher patient satisfaction as compared to general hospitals.

Europe automated breast ultrasound systems market size is poised to surpass USD 950 million by 2030. The surging prevalence of breast cancer due to unhealthy lifestyles and dietary habits along with genetic predisposition towards the disease will propel the demand for ABUS. The region has a solid footprint of industry leaders that are introducing novel products. For instance, in September 2020, French medical imaging expert SuperSonic Imagine launched its Hologic catalog in Austria, Germany, and Switzerland to enhance diagnostic reliability and ensure streamlined workflow.